Literature DB >> 24477651

Prostate-specific membrane antigen as a marker of pancreatic cancer cells.

He Ren1, Huan Zhang, Xiuchao Wang, Junxiu Liu, Zhanna Yuan, Jihui Hao.   

Abstract

The aim of this study was to identify the expression of prostate-specific membrane antigen (PSMA) and analyze the correlation between PSMA with clinical characteristics in patients with pancreatic cancer. The expression of PSMA protein and mRNA was detected by immunohistochemistry and real-time quantitative polymerase chain reaction in pancreatic cancer tissues, pancreatic intraepithelial neoplasia or normal pancreatic tissues, respectively. And clinical characteristics and prognosis of patients were investigated. PSMA was expressed in pancreatic cancer cells, both in protein and mRNA levels. Moreover, the PSMA levels were associated with the prognosis of patients with pancreatic ductal adenocarcinoma. The overall survival time of pancreatic cancer patients with high expression of PSMA was significantly shorter than that of the low ones. Moreover, the PSMA levels were correlated with clinicopathological features including the histological grade and pathological tumor-node-metastasis stage. PSMA is involved in the carcinogenesis of pancreatic cancer, and it might serve as a potential therapeutic target for pancreatic cancer.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24477651     DOI： 10.1007/s12032-014-0857-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  17 in total

Review 1.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

Review 2.  Antiplatelet antibodies in chronic immune thrombocytopenia and their role in platelet destruction and defective platelet production.

Authors:  Robert McMillan
Journal:  Hematol Oncol Clin North Am       Date:  2009-12       Impact factor: 3.722

3.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Authors:  S S Chang; V E Reuter; W D Heston; N H Bander; L S Grauer; P B Gaudin
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

4.  Leptin enhances in vitro secretion of IgG antiplatelet antibodies by splenocytes and peripheral blood mononuclear cells from patients with chronic idiopathic thrombocytopenic purpura.

Authors:  He Ren; Hui Zhao; Tingting Wang; Yanhui Yang; Zhibo Han; Bin Liu; Zida Wu; Jie Tao; Bin Zhou; Lei Zhang; Renchi Yang; Zhong Chao Han
Journal:  Clin Immunol       Date:  2006-06-13       Impact factor: 3.969

Review 5.  Prostate-specific membrane antigen-based imaging.

Authors:  Joseph R Osborne; Naveed H Akhtar; Shankar Vallabhajosula; Alok Anand; Kofi Deh; Scott T Tagawa
Journal:  Urol Oncol       Date:  2012-05-31       Impact factor: 3.498

6.  New alternatively spliced variant of prostate-specific membrane antigen PSM-E suppresses the proliferation, migration and invasiveness of prostate cancer cells.

Authors:  Kai-Yuan Cao; Lin Xu; Ding-Mei Zhang; Xiao-Ming Zhang; Tian Zhang; Xia He; Zhu Wang; Fa-Shen Feng; Shao-Peng Qiu; Guan-Xin Shen
Journal:  Int J Oncol       Date:  2012-02-06       Impact factor: 5.650

7.  Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer.

Authors:  Philipp Wolf; Nikolaus Freudenberg; Patrick Bühler; Karen Alt; Wolfgang Schultze-Seemann; Ulrich Wetterauer; Ursula Elsässer-Beile
Journal:  Prostate       Date:  2010-04-01       Impact factor: 4.104

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

Review 9.  Targeted therapies for prostate cancer against the prostate specific membrane antigen.

Authors:  U Elsässer-Beile; P Bühler; P Wolf
Journal:  Curr Drug Targets       Date:  2009-02       Impact factor: 3.465

10.  Prostate-specific membrane antigen-based therapeutics.

Authors:  Naveed H Akhtar; Orrin Pail; Ankeeta Saran; Lauren Tyrell; Scott T Tagawa
Journal:  Adv Urol       Date:  2011-07-17
View more
  14 in total

1.  Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases.

Authors:  Mariz Kasoha; Clara Unger; Erich-Franz Solomayer; Rainer M Bohle; Claudia Zaharia; Fadi Khreich; Stefan Wagenpfeil; Ingolf Juhasz-Böss
Journal:  Clin Exp Metastasis       Date:  2018-02-10       Impact factor: 5.150

Review 2.  Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.

Authors:  James J Vornov; Diane Peters; Mike Nedelcovych; Kristen Hollinger; Rana Rais; Barbara S Slusher
Journal:  Neurochem Res       Date:  2019-11-20       Impact factor: 3.996

3.  Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.

Authors:  Ken Herrmann; Christina Bluemel; Martina Weineisen; Margret Schottelius; Hans-Jürgen Wester; Johannes Czernin; Uta Eberlein; Seval Beykan; Constantin Lapa; Hubertus Riedmiller; Markus Krebs; Saskia Kropf; Andreas Schirbel; Andreas K Buck; Michael Lassmann
Journal:  J Nucl Med       Date:  2015-04-16       Impact factor: 10.057

Review 4.  The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.

Authors:  James C Evans; Meenakshi Malhotra; John F Cryan; Caitriona M O'Driscoll
Journal:  Br J Pharmacol       Date:  2016-09-23       Impact factor: 8.739

Review 5.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

Review 6.  Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer.

Authors:  A Fucic; A Aghajanyan; Z Culig; N Le Novere
Journal:  Pathol Oncol Res       Date:  2018-09-16       Impact factor: 3.201

7.  Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.

Authors:  Kyle Current; Catherine Meyer; Clara E Magyar; Christine E Mona; Joel Almajano; Roger Slavik; Andreea D Stuparu; Chloe Cheng; David W Dawson; Caius G Radu; Johannes Czernin; Katharina Lueckerath
Journal:  Clin Cancer Res       Date:  2020-01-13       Impact factor: 12.531

8.  Neovascular Prostate-Specific Membrane Antigen Expression Is Associated with Improved Overall Survival under Palliative Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma.

Authors:  Katharina Stock; Konrad Steinestel; Rebekka Wiesch; Jan-Henrik Mikesch; Anna Hansmeier; Marcel Trautmann; Nora Beller; Jan Rehkämper; Eva Wardelmann; Birthe Heitkötter; Wolfgang Hartmann; Jan Sperveslage; Sebastian Huss
Journal:  Biomed Res Int       Date:  2017-10-25       Impact factor: 3.411

9.  Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment.

Authors:  F A Vuijk; L D A N de Muynck; L C Franken; O R Busch; J W Wilmink; M G Besselink; B A Bonsing; S S Bhairosingh; P J K Kuppen; J S D Mieog; C F M Sier; A L Vahrmeijer; J Verheij; A Fariňa-Sarasqueta; R J Swijnenburg
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

Review 10.  Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma.

Authors:  Q Li; S H Maier; P Li; J Peterhansl; C Belka; J Mayerle; U M Mahajan
Journal:  Radiat Oncol       Date:  2020-08-05       Impact factor: 3.481
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.